No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial-Reference-Cited by-同舟云学术

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial

Published:2011-10 Issue:8 Volume:80 Page:841-850
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Hansen Ditte,Rasmussen Knud,Danielsen Henning,Meyer-Hofmann Helmut,Bacevicius Egidijus,Lauridsen Thomas G.,Madsen Jens K.,Tougaard Birgitte G.,Marckmann Peter,Thye-Roenn Peter,Nielsen Jørgen E.,Kreiner Svend,Brandi Lisbet

Publisher

Elsevier BV

Subject

Nephrology

Reference56 articles.

1. Clinical epidemiology of cardiovascular disease in chronic renal disease;Foley;Am J Kidney Dis,1998

2. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization;Go;N Engl J Med,2004

3. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis;Goodman;N Engl J Med,2000

4. Association of serum phosphate with vascular and valvular calcification in moderate CKD;Adeney;J Am Soc Nephrol,2009

5. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study;Block;Am J Kidney Dis,1998

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data;PLOS ONE;2024-05-31

2. Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study;Journal of Medical Internet Research;2024-05-03

3. Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study (Preprint);2023-05-02

4. Vitamine und Mineralstoffpräparate;Arzneiverordnungs-Report 2023;2023

5. Évolution de l’incidence et des résultats à 12 mois de la parathyroïdectomie : 40 ans d’expérience dans un centre de dialyse avec deux services de chirurgie successifs;Néphrologie & Thérapeutique;2022-12